374 filings
6-K
BNTX
BioNTech SE
8 Apr 24
Invitation to the Annual General Meeting 2024
5:05pm
6-K
BNTX
BioNTech SE
8 Apr 24
Current report (foreign)
7:12am
6-K
BNTX
BioNTech SE
22 Mar 24
Current report (foreign)
5:33pm
20-F
2023 FY
BNTX
BioNTech SE
Annual report (foreign)
20 Mar 24
7:57am
6-K
BNTX
BioNTech SE
20 Mar 24
BioNTech Announces Fourth Quarter and Full Year 2023
7:33am
6-K
7nmf 9vmn68qvn
20 Mar 24
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
7:11am
6-K
n2oie70js0 y6xk
11 Mar 24
BioNTech to Present Clinical Data Updates For Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
9:04am
6-K
cfhrwwgyv rxlju5
7 Mar 24
BioNTech Announces Planned Retirement of Sean Marett
8:41am
144
npw4egd6
28 Feb 24
Notice of proposed sale of securities
6:26pm
SC 13D
u75og21
21 Feb 24
Autolus Therapeutics / BioNTech SE ownership change
5:01pm
S-8
k7pb0ovd3t92ow0g
15 Feb 24
Registration of securities for employees
4:10pm
SC 13G/A
fkmf7dgmg0ggva8w8h
14 Feb 24
BioNTech SE / Medine GmbH ownership change
7:26am
6-K
5d2p2elv7s0w3rha
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:08am
SC 13G/A
i0fw6
7 Feb 24
BioNTech SE / ATHOS KG ownership change
5:03pm
6-K
qfov ax7e
31 Jan 24
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
7:47am
6-K
pr7h9lk
22 Jan 24
Current report (foreign)
9:14am
6-K
iziax
9 Jan 24
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
7:01am
144
5ly1hz50
4 Jan 24
Notice of proposed sale of securities
8:02am
6-K
xdxjc kcfm
21 Dec 23
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
4:02pm
6-K
cde8hgrdep4zo0l
18 Dec 23
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
4:22pm